CG Oncology provided updated data on BOND-003 Cohort C, showing a 41.8% complete response rate for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer.
90% of 12-month responders remained disease-free at 24 months, reaffirming the treatment's durability.
The safety profile of cretostimogene remained consistent with no severe treatment-related adverse events reported.
Complete Response Rate
Robust 24-month complete response rate of 41.8% observed in BOND-003 Cohort C.
Durability
90% of 12-month responders remained disease-free at 24 months.
Safety Profile
No grade 3 or greater treatment-related adverse events reported for cretostimogene.
Presentation
Results presented by Dr. Trinity J. Bivalacqua at the New England Section of the American Urological Association's meeting.
Future Plans
CG Oncology aiming to submit BLA for cretostimogene in the fourth quarter of the current year.
- The Phase 3 BOND-003 Cohort C study demonstrated a 41.8% complete response rate at 24 months, indicating the potential of cretostimogene as a breakthrough treatment for bladder cancer patients.
- Patients in the study showed high durability and low adverse events, positioning cretostimogene as a promising bladder-sparing therapeutic option.
- The data suggests that cretostimogene could offer a significant advancement for high-risk non-muscle invasive bladder cancer patients unresponsive to BCG treatment.
The updated data from BOND-003 Cohort C highlights the promising efficacy and safety profile of cretostimogene, signaling a potential advancement in the treatment of high-risk non-muscle invasive bladder cancer.